Drug
CVM-1118
CVM-1118 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Recruiting1
Active, not recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
recruiting133%
active_not_recruiting133%
terminated133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_2
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
NCT05257590
active_not_recruitingphase_2
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
NCT03600233
terminatedphase_2
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
NCT03582618
Clinical Trials (3)
Showing 3 of 3 trials
NCT05257590Phase 2
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
NCT03600233Phase 2
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
NCT03582618Phase 2
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3